TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17030521

Group type: EXPERIMENTAL
Intervention: Caldaret 57.5 mg (lower dose)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Caldaret 172.5 mg (higher dose)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study: 12622853

Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Number of subjects: 73

Group type: COMPARATOR
Intervention: Fluoride toothpaste
Number of subjects: 73
Study: 11043885

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 0
Study: 8858533

Group type: EXPERIMENTAL
Intervention: Chemotherapy (combinations of Adriamycin and Dacarbazine or Ifosfamide and Mesna)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy (interferon‐alpha)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study: 1536112

Group type: EXPERIMENTAL
Intervention: Vertical sternal lead
Number of subjects: 50
Study: 6391162

Group type: EXPERIMENTAL
Intervention: Low-sucrose diet (less than 3 g of sucrose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sucrose diet (220 g of sucrose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate-sucrose diet (120 g of sucrose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet (120 g of sucrose and 50 percent carbohydrate)
Number of subjects: 0
Study: 31986325

Group type: EXPERIMENTAL
Intervention: Topical ozone therapy (ozone hydrotherapy followed by ozonated oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (tap water and basal oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical ozone therapy
Number of subjects: 0
Study: 30382930

Group type: EXPERIMENTAL
Intervention: Whole-body neuromuscular electrical stimulation (WBS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 36
Study: 27776673

Group type: EXPERIMENTAL
Intervention: READY First (Motivational Interviewing intervention)
Number of subjects: 244

Group type: COMPARATOR
Intervention: WLC (Waitlist Control)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: READY First
Number of subjects: 244

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 244
Study: 24576855

Group type: EXPERIMENTAL
Intervention: 2-h aerobic exercise session (LA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1-h aerobic exercise session (MA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1-h resistance exercise session (MR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 2-h resistance exercise session (LR)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no exercise; CON)
Number of subjects: 8
Study: 22153696

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids 2 g daily for 2 months
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg daily for 2 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 20167147

Group type: EXPERIMENTAL
Intervention: FSC, 100/50 micrograms twice daily
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: FSC twice daily + FPANS, 200 micrograms once daily
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: FSC twice daily + MON, 10 mg once daily
Number of subjects: 1385

Group type: COMPARATOR
Intervention: MON once daily
Number of subjects: 1385
Study: 17912226

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study: 16288485

Group type: EXPERIMENTAL
Intervention: Docetaxel-cisplatin (DC)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Docetaxel-carboplatin (DCb)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Vinorelbine-cisplatin (VC)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Comparison of elderly patients to younger patients
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Toxicity profile
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 401
Study: 11884912

Group type: EXPERIMENTAL
Intervention: Isometric axial rotation exertion at 80% maximum voluntary contraction
Number of subjects: 24
Study: 10707139

Group type: EXPERIMENTAL
Intervention: Automated system for the measurement of erythrocyte sedimentation rate (ESR)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Manual Seditainer method
Number of subjects: 212
Study: 8950773

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Danaparoid
Number of subjects: 188

Group type: COMPARATOR
Intervention: Utrecht bleeding risk score
Number of subjects: 188

Group type: COMPARATOR
Intervention: Landefeld bleeding risk index
Number of subjects: 188
Study: 2013485

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 3234
Study: 7036726

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg per day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg per day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg and 240 mg
Number of subjects: 48
Study: 29463913

Group type: EXPERIMENTAL
Intervention: Oxycodone 5.0 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oxycodone 2.5 mg + active cannabis (5.6% THC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oxycodone 2.5 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Active cannabis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oxycodone + cannabis
Number of subjects: 18
Study: 27869110

Group type: EXPERIMENTAL
Intervention: Paced audio serial addition task (PASAT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Neutral intervention (peaceful music)
Number of subjects: 15
Study: 25765671

Group type: EXPERIMENTAL
Intervention: 25g whey preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24331680

Group type: EXPERIMENTAL
Intervention: Choose Health program (cognitive behavioural lifestyle intervention)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 63
Study: 20142658

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at a median dose of 81.5 microg/kg
Number of subjects: 272
Study: 18566863

Group type: EXPERIMENTAL
Intervention: Specific oral anticoagulation treatment educational program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific educational program)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 0
Study: 16629421

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a, Avonex) 60 microg weekly intramuscular injections for 24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14762699

Group type: EXPERIMENTAL
Intervention: Iodine-131 therapy (1.8-10.4 GBq single activity, 5.5-43.7 GBq total activity) after total thyroidectomy and lymph node dissection if applicable
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-resolution computed tomography (HRCT)
Number of subjects: 42
Study: 10730072

Group type: EXPERIMENTAL
Intervention: Aboral pouch construction
Number of subjects: 25

Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction
Number of subjects: 25
Study: 9186348

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 8266015

Group type: EXPERIMENTAL
Intervention: Follow-up intervals varying from 6 to 48 months (with 53 patients allocated to 6 months)
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Follow-up strategy
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Colonoscopy examinations
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Adenoma-carcinoma conversion rates
Number of subjects: 1056
Study: 4039155

Group type: EXPERIMENTAL
Intervention: Flupirtine (100 mg, 3 consecutive doses)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pentazocine (50 mg, single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2906876

Group type: EXPERIMENTAL
Intervention: Mifentidine 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mifentidine 40 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mifentidine 80 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29614679

Group type: EXPERIMENTAL
Intervention: Composite supplement containing astaxanthin and sesamin (AS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 21
Study: 27869113

Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) for 8 weeks, 4-6 sets of 20 seconds at maximal intensity with a ratio effort/recovery of 1:3 to 1:1
Number of subjects: 35

Group type: COMPARATOR
Intervention: Continuous aerobic exercise for 8 weeks
Number of subjects: 35
Study: 24563922

Group type: EXPERIMENTAL
Intervention: Chloroprocaine (CP) 40 mg intrathecally with 500 ml pre-load (CP+)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Chloroprocaine (CP) 40 mg intrathecally without pre-load (CP−)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine (L) 60 mg intrathecally with 500 ml pre-load (L+)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine (L) 60 mg intrathecally without pre-load (L−)
Number of subjects: 100
Study: 23656510

Group type: EXPERIMENTAL
Intervention: computerized cognitive remediation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: games
Number of subjects: 28
Study: 20703256

Group type: EXPERIMENTAL
Intervention: p190 ALL
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: p210 ALL
Number of subjects: 82

Group type: COMPARATOR
Intervention: p210 CML
Number of subjects: 82
Study: 18622274

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study: 17099426

Group type: EXPERIMENTAL
Intervention: Incremental plantar flexion exercise at 2, 3, 4, and 5 W
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ankle brachial pressure index measurement
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Run-off resistance determined on MR angiograms
Number of subjects: 12
Study: 14633959

Group type: EXPERIMENTAL
Intervention: Intravenous bolus somatostatin 250 microg given immediately after diagnostic cholangiopancreatography
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 10966906

Group type: EXPERIMENTAL
Intervention: Glucose (50 g carbohydrate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Potatoes (50 g carbohydrate)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Barley (50 g carbohydrate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9356550

Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Resistant starch
Number of subjects: 15

Group type: COMPARATOR
Intervention: Glucose (placebo)
Number of subjects: 15
Study: 8470531

Group type: EXPERIMENTAL
Intervention: Scopolamine (two pieces of Scopoderm-TTS patches)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study: 3511703

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet combined with antiandrogenic therapy (cyproterone acetate, 50 mg/day, plus ethinyl estradiol, 0.05 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypocaloric diet without antiandrogenic therapy
Number of subjects: 0
Study: 30932951

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 9322

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 9322

Group type: EXPERIMENTAL
Intervention: TAF
Number of subjects: 9322

Group type: COMPARATOR
Intervention: TDF
Number of subjects: 9322
Study: 29262272

Group type: EXPERIMENTAL
Intervention: CMR+CAFF
Number of subjects: 8

Group type: COMPARATOR
Intervention: CMR
Number of subjects: 8

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 8
Study: 26806591

Group type: EXPERIMENTAL
Intervention: Endodontic debridement
Number of subjects: 95

Group type: COMPARATOR
Intervention: No endodontic debridement
Number of subjects: 95
Study: 24102369

Group type: EXPERIMENTAL
Intervention: Er:YAG AFL‐PDT
Number of subjects: 21

Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 21
Study: 23030656

Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 19

Group type: COMPARATOR
Intervention: Active recovery
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both recovery types
Number of subjects: 19
Study: 20413988

Group type: EXPERIMENTAL
Intervention: Probiotic Escherichia coli strain administered (1 mL within 48 hours after birth, then 3 times a week for 4 weeks)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control infants of allergic mothers
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control infants of healthy mothers
Number of subjects: 158
Study: 18687167

Group type: EXPERIMENTAL
Intervention: Amino-bisphosphonates treatment
Number of subjects: 234
Study: 16483520

Group type: EXPERIMENTAL
Intervention: Telephone administration of SF-36
Number of subjects: 351

Group type: COMPARATOR
Intervention: Self-administration of SF-36
Number of subjects: 351
Study: 11954988

Group type: EXPERIMENTAL
Intervention: 200 ppm methyl ethyl ketone exposure
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 19
Study: 10981547

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 72

Group type: COMPARATOR
Intervention: ACEI (enalapril)
Number of subjects: 72
Study: 8955865

Group type: EXPERIMENTAL
Intervention: Medium molecular weight (MMW) hydroxyethyl starch (HES) 200/0.5
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low molecular weight (LMW) hydroxyethyl starch (HES) 40/0.5
Number of subjects: 20
Study: 1488514

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg (t.i.d.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3929692

Group type: EXPERIMENTAL
Intervention: Futraful alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of MMC and Futraful
Number of subjects: 0

Group type: COMPARATOR
Intervention: MMC alone
Number of subjects: 0
Study: 30994192

Group type: EXPERIMENTAL
Intervention: TIPP
Number of subjects: 251

Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Both TIPP and Lichtenstein
Number of subjects: 251
Study: 28193189

Group type: EXPERIMENTAL
Intervention: High dose DHA supplementation (1000 mg DHA/d)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (200 mg DHA/d from prenatal supplement)
Number of subjects: 1200
Study: 25195923

Group type: EXPERIMENTAL
Intervention: Mailed gFOBT kit and second mailed CRC screening invitation
Number of subjects: 3584

Group type: COMPARATOR
Intervention: Second mailed CRC screening invitation alone
Number of subjects: 3584
Study: 23092711

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 0
Study: 21816787

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 84
Study: 19796455

Group type: EXPERIMENTAL
Intervention: Dutasteride 3.5 mg and bicalutamide 50 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo and bicalutamide 50 mg once daily
Number of subjects: 0
Study: 17003246

Group type: EXPERIMENTAL
Intervention: Graphic organizers
Number of subjects: 0

Group type: COMPARATOR
Intervention: No graphic organizers (control group)
Number of subjects: 0
Study: 12700715

Group type: EXPERIMENTAL
Intervention: Clozapine (CLZ)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ)
Number of subjects: 160
Study: 11041569

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9153544

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 8095008

Group type: EXPERIMENTAL
Intervention: Early zidovudine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Later zidovudine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked therapy continuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmasked treatment and follow-up
Number of subjects: 0
Study: 3680580

Group type: EXPERIMENTAL
Intervention: Nalmefene 50 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nalmefene 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nalmefene 200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nalmefene 300 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg q12h for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30218012

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Routine antenatal care (control)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) with higher adherence
Number of subjects: 220
Study: 27496186

Group type: EXPERIMENTAL
Intervention: Ponseti method
Number of subjects: 39

Group type: COMPARATOR
Intervention: Early tibialis anterior tendon transfer (TATT)
Number of subjects: 39
Study: 26509991

Group type: EXPERIMENTAL
Intervention: Laser-Lok implants (LL)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Non-Laser-Lok implants (NLL)
Number of subjects: 77
Study: 23398493

Group type: EXPERIMENTAL
Intervention: Combined cognitive behavioral therapy (CBT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Self-control desensitization
Number of subjects: 76
Study: 22026413

Group type: EXPERIMENTAL
Intervention: Intraarticular ropivacaine infusion (0.5%, 2 mL/h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Extraarticular ropivacaine infusion (0.5%, 2 mL/h)
Number of subjects: 36
Study: 18836357

Group type: EXPERIMENTAL
Intervention: Anterior lumbar disc replacement
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-level lumbar transforaminal interbody fusion (TLIF)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anterior spinal fusion (ASF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anterior and posterior spinal fusion (ASF/PSF)
Number of subjects: 20
Study: 17297828

Group type: EXPERIMENTAL
Intervention: 40 mL of 1% mepivacaine with adrenaline plus 4 mL of NaHCO3 and 1 mL of saline (Group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mL of 1% mepivacaine with adrenaline plus 4 mL of NaHCO3 and 150 microg of clonidine (Group IV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mL of 1% mepivacaine with 150 microg of clonidine plus 4mL of saline (Group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 40 mL of 1% mepivacaine with adrenaline plus 5 mL of saline (Group I - Control)
Number of subjects: 60
Study: 14520605

Group type: EXPERIMENTAL
Intervention: Repaglinide (2 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11119051

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) as add-on therapy
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) in patients with central area epilepsies
Number of subjects: 237
Study: 9207646

Group type: EXPERIMENTAL
Intervention: High resolution fractal dimension (D)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: High resolution fractal dimension (D) in randomized patient group
Number of subjects: 484
Study: 7982347

Group type: EXPERIMENTAL
Intervention: Unusual forms of pulmonary embolism
Number of subjects: 0
Study: 2586439

Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy (CDDP+VDS, IL2+LAK cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro stimulated LAK cells (St-LAK) administered locally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAK-BAI (bronchial arterial infusion) combined with radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (CDDP + VDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group A
Number of subjects: 0
Study: 1135876

Group type: EXPERIMENTAL
Intervention: pHisohex
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hyperphaze
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 36
Study: 31475938

Group type: EXPERIMENTAL
Intervention: Scapular mobilization (Group 1, n=27)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Manual posterior capsule stretching (Group 2, n=27)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combined application of scapular mobilization and manual posterior capsule stretching (n=54)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 54
Study: 29214925

Group type: EXPERIMENTAL
Intervention: ISO + EXE (100 mg of isoflavone and exercise)
Number of subjects: 32

Group type: COMPARATOR
Intervention: PLA + EXE (placebo and exercise)
Number of subjects: 32
Study: 25994188

Group type: EXPERIMENTAL
Intervention: Shenfu injection loading (100 ml 5% glucose injection + 50 ml Shenfu injection)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (150 ml 5% glucose injection)
Number of subjects: 160
Study: 24952857

Group type: EXPERIMENTAL
Intervention: NT‐proBNP-guided treatment
Number of subjects: 340

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 340
Study: 22547382

Group type: EXPERIMENTAL
Intervention: Calcium phosphate coated (HA) cups
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Porous-coated (PC) cups
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal healthy hip (reference group)
Number of subjects: 8
Study: 19282610

Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 92
Study: 17890496

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 64

Group type: COMPARATOR
Intervention: NCEP diet (control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Group support
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Meeting attendance
Number of subjects: 64
Study: 15165413

Group type: EXPERIMENTAL
Intervention: Physiological coherence condition
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline condition of 'normal' psychophysiologic function
Number of subjects: 26